These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35073787)

  • 1. Recent Insights on Glutamatergic Dysfunction in Alzheimer's Disease and Therapeutic Implications.
    Pinky PD; Pfitzer JC; Senfeld J; Hong H; Bhattacharya S; Suppiramaniam V; Qureshi I; Reed MN
    Neuroscientist; 2023 Aug; 29(4):461-471. PubMed ID: 35073787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairments of glutamatergic synaptic transmission in Alzheimer's disease.
    Zott B; Konnerth A
    Semin Cell Dev Biol; 2023 Apr; 139():24-34. PubMed ID: 35337739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunction of NMDA receptors in Alzheimer's disease.
    Zhang Y; Li P; Feng J; Wu M
    Neurol Sci; 2016 Jul; 37(7):1039-47. PubMed ID: 26971324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice" on page 513.
    Gulyaeva NV
    J Neurochem; 2021 Feb; 156(4):399-402. PubMed ID: 33276416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors.
    Mota SI; Ferreira IL; Rego AC
    Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex.
    Sokolow S; Luu SH; Nandy K; Miller CA; Vinters HV; Poon WW; Gylys KH
    Neurobiol Dis; 2012 Jan; 45(1):381-7. PubMed ID: 21914482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic Glutamate Receptors in Alzheimer's Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future.
    Srivastava A; Das B; Yao AY; Yan R
    J Alzheimers Dis; 2020; 78(4):1345-1361. PubMed ID: 33325389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy.
    Bukke VN; Archana M; Villani R; Romano AD; Wawrzyniak A; Balawender K; Orkisz S; Beggiato S; Serviddio G; Cassano T
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-synaptic scaffolding protein interactions with glutamate receptors in synaptic dysfunction and Alzheimer's disease.
    Proctor DT; Coulson EJ; Dodd PR
    Prog Neurobiol; 2011 Apr; 93(4):509-21. PubMed ID: 21382433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAPGEF2 mediates oligomeric Aβ-induced synaptic loss and cognitive dysfunction in the 3xTg-AD mouse model of Alzheimer's disease.
    Jang YN; Jang H; Kim GH; Noh JE; Chang KA; Lee KJ
    Neuropathol Appl Neurobiol; 2021 Aug; 47(5):625-639. PubMed ID: 33345400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking.
    Guntupalli S; Widagdo J; Anggono V
    Neural Plast; 2016; 2016():3204519. PubMed ID: 27073700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD mice.
    Pfitzer J; Pinky PD; Perman S; Redmon E; Cmelak L; Suppiramaniam V; Coric V; Qureshi IA; Gramlich MW; Reed MN
    J Neurochem; 2025 Jan; 169(1):e16215. PubMed ID: 39214859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease.
    Paula-Lima AC; Brito-Moreira J; Ferreira ST
    J Neurochem; 2013 Jul; 126(2):191-202. PubMed ID: 23668663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease.
    Rudy CC; Hunsberger HC; Weitzner DS; Reed MN
    Aging Dis; 2015 Mar; 6(2):131-48. PubMed ID: 25821641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease.
    Rodriguez-Perdigon M; Tordera RM; Gil-Bea FJ; Gerenu G; Ramirez MJ; Solas M
    Hippocampus; 2016 Oct; 26(10):1303-12. PubMed ID: 27258819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease.
    Zeng Y; Zhang J; Zhu Y; Zhang J; Shen H; Lu J; Pan X; Lin N; Dai X; Zhou M; Chen X
    J Neurochem; 2015 Apr; 133(1):38-52. PubMed ID: 25661995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synapse as a treatment avenue for Alzheimer's Disease.
    Peng L; Bestard-Lorigados I; Song W
    Mol Psychiatry; 2022 Jul; 27(7):2940-2949. PubMed ID: 35444256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.